A vial labelled "5 mg" rarely contains 5 mg of peptide. It contains 5 mg of peptide salt. The difference between those two statements is the counter-ion. Whether that counter-ion is trifluoroacetate or acetate changes your net peptide content, your molarity calculations, and, in some cell models, your results.
Why synthetic peptides carry counter-ions at all
Almost every research peptide on the market is made by solid-phase peptide synthesis. The chain is built residue by residue on a resin. Protected side chains keep the chemistry orderly. At the end, the whole assembly has to be cut free. The standard cleavage cocktail is dominated by trifluoroacetic acid: typically 90 to 95% TFA with scavengers. That is strong enough to release the peptide and remove acid-labile protecting groups without destroying the backbone.
TFA is also the standard ion-pairing additive in preparative reverse-phase HPLC, the purification step that follows. So the peptide meets TFA twice: once during cleavage, once during clean-up. Basic residues, including lysine, arginine, histidine, and the free N-terminal amine, are protonated under those conditions and pair with trifluoroacetate anions. Lyophilisation removes water and free acid, but not the ion pairs. What comes out of the freeze-dryer is a peptide trifluoroacetate salt.
This is not a defect and it is not a sign of a careless supplier. It is the default output of the dominant synthesis route. A peptide sold without an explicit salt-form statement is, in the overwhelming majority of cases, a TFA salt.
How much TFA actually remains
Residual TFA content in lyophilised peptides is commonly reported in the range of a few per cent up to roughly 20 to 30% of total mass. That figure depends on the number of basic residues, the peptide's length, and how thoroughly it was lyophilised or re-lyophilised. A short, neutral sequence with one basic site carries relatively little. A highly cationic peptide with several arginines and lysines can carry a great deal. Each protonated site holds its own counter-ion.
Two contributions are worth separating. Stoichiometric TFA is bound to basic sites and does not come off with additional drying. Free or excess TFA is trapped residual acid. That fraction can be reduced by repeated lyophilisation from dilute acid or by ion exchange. Total measured TFA on an analytical report is the sum of both.
Quantification is usually by ion chromatography, fluorine-19 NMR, or capillary electrophoresis. The important point for anyone planning experiments is that the number is not negligible. It is not constant between batches or between sequences.
Documented effects on sensitive cell assays
The reason this matters beyond bookkeeping is that trifluoroacetate is not inert in every system. Published cell-culture work has documented TFA-attributable effects at low millimolar and even high micromolar concentrations in some models:
- reduced proliferation
- altered viability readings
- shifts in membrane potential in electrophysiology preparations
- interference in assays sensitive to intracellular pH
Effects have also been noted in sensitive primary cultures, in certain neuronal preparations, and in mitochondrial function assays.
The concentrations at which this happens deserve attention. Consider a peptide applied at 10 µM, where the material carries 20% TFA by mass. The trifluoroacetate concentration in the well can then approach or exceed the peptide concentration in molar terms. This is because TFA's molecular weight is small relative to a peptide's.
In a study designed around nanomolar receptor occupancy, this is usually irrelevant. It can become a confound in a high-concentration cytotoxicity screen or in a long-incubation proliferation assay. The same applies to any experiment where the endpoint is itself a general measure of cell health. There, the confound looks exactly like a peptide effect.
Two practical consequences follow. First, a vehicle control matched for counter-ion content, not just buffer alone, is the only way to separate peptide activity from counter-ion activity. Second, in models known to be sensitive, acetate-form material removes the ambiguity. It does not leave you to argue it away in the discussion section.
Salt exchange, and why acetate costs more
Converting a TFA salt to an acetate salt is a deliberate extra step. The usual routes are:
- ion-exchange chromatography on an anion-exchange resin loaded in the acetate form
- repeated lyophilisation from dilute acetic acid
- re-running the final purification with an acetate-based ion-pairing system rather than TFA
Each approach costs material, time and yield. Exchange steps involve additional handling losses and extra lyophilisation cycles. They also involve a further round of analytics to confirm the exchange actually worked and that the peptide survived it.
Acetate is not the only alternative. Hydrochloride salts are common in some contexts, and formate or ammonium acetate systems appear in others. Acetate dominates in research supply because acetic acid is volatile, biologically familiar at low concentrations, and well tolerated by most cell systems.
The exchange is real work with real yield loss. An acetate-form peptide therefore costs meaningfully more per milligram than the same sequence as a TFA salt. When a listing shows a large price gap between two apparently identical products, salt form is one of the first things worth checking. The analytical documentation is worth checking alongside it. That is covered in more depth in our guide to reading peptide purity reports.
How salt form changes the maths
This is where salt form quietly wrecks reproducibility. Three different numbers are often conflated:
- Gross mass: what the balance reads, or what the vial label states. Peptide plus counter-ion plus residual water.
- Net peptide content: gross mass corrected for counter-ion and water. Sometimes given as "peptide content" on an analytical certificate, typically 70 to 90% for a TFA salt.
- Purity: the HPLC figure, describing what fraction of the peptide present is the target sequence. A peptide can be 99% pure by HPLC and still be only 78% peptide by mass.
Those last two are independent. Treating a 98% purity figure as though it were 98% peptide content systematically overstates concentration. Suppose the label says 5 mg, peptide content is 76%, and you reconstitute assuming 5 mg of peptide. Every stated concentration in that experiment is then wrong in the same direction. The true concentration is 76% of the figure you recorded. The recorded number therefore overstates reality by about a third.
Switching supplier or batch mid-study, from a TFA salt with 76% content to an acetate salt with 88%, introduces a silent 16% step change in effective concentration. That will show up as unexplained variance between experimental blocks.
For molar calculations, use net peptide mass and the molecular weight of the free base peptide, not the salt. Suppliers occasionally quote a salt-adjusted molecular weight. Mixing that with a net-content correction double-counts the counter-ion. Record salt form, peptide content and batch number in the same place you record concentrations. Reconstitution practice is covered separately in our reconstitution and storage guide.
Solubility and stability differences
Salt form has modest but real effects on physical behaviour. TFA salts often dissolve readily in water, because the trifluoroacetate ion pairs are well solvated. The residual acid lowers the pH of a concentrated stock. That can help peptides that are more soluble under acidic conditions. That same acidity is a liability for acid-sensitive sequences over long storage. It can also shift the pH of small-volume additions to weakly buffered media.
Acetate salts tend to give near-neutral solutions. They are generally the better choice for peptides intended for prolonged incubation in physiological buffers. Some sequences show slightly poorer aqueous solubility as the acetate. Hydrophobic peptides may need a small proportion of organic co-solvent regardless of counter-ion.
Trifluoroacetate also has one specific analytical drawback. It suppresses ionisation in positive-mode electrospray mass spectrometry and produces adducts. TFA-form material can therefore complicate quantitative LC-MS work.
When TFA form is perfectly adequate
Most of the time, it is. TFA-salt material is appropriate:
- for analytical standards and identity confirmation
- for binding and receptor-activation assays run at nanomolar concentrations
- for enzymatic and biochemical work in well-buffered systems
- for structural studies
- for any experiment where dilution factors put counter-ion concentration several orders of magnitude below the levels at which effects have been reported
Acetate form earns its premium in a narrower set of cases:
- sustained cell-culture exposure at micromolar concentrations or above
- primary cells and stem-cell cultures
- electrophysiology
- mitochondrial and metabolic assays
- sensitive immunological readouts such as cytokine panels
- studies in rodent models where cumulative counter-ion exposure over a multi-week protocol becomes a genuine variable
Regulatory-adjacent and preclinical work generally specifies acetate or another defined pharmaceutical salt for the same reason.
The decision is not about quality tiers. It is about whether the counter-ion sits inside your assay's window of sensitivity. Answer that first. Then check that the analytical documentation actually reports salt form and peptide content, rather than leaving you to guess. A certificate that gives purity alone tells you only half of what you need. Peptides discussed in this context, including BPC-157 and other commonly studied sequences, are listed in the shop.
All products are supplied strictly for in-vitro laboratory research use only. Not for human or veterinary use.